Science advances · 2023
Druggable proteins influencing cardiac structure and function: Implications for heart failure therapies and cancer cardiotoxicity.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schmidt Amand F, Bourfiss Mimount, Alasiri Abdulrahman, Puyol-Anton Esther, Chopade Sandesh, van Vugt Marion, van der Laan Sander W, Gross Christian, Clarkson Chris, Henry Albert, Lumbers Tom R, van der Harst Pim, Franceschini Nora, Bis Joshua C, Velthuis Birgitta K, Te Riele Anneline S J M, Hingorani Aroon D, Ruijsink Bram, Asselbergs Folkert W, van Setten Jessica, Finan Chris
Аннотация
Dysfunction of either the right or left ventricle can lead to heart failure (HF) and subsequent morbidity and mortality. We performed a genome-wide association study (GWAS) of 16 cardiac magnetic resonance (CMR) imaging measurements of biventricular function and structure. Cis-Mendelian randomization (MR) was used to identify plasma proteins associating with CMR traits as well as with any of the following cardiac outcomes: HF, non-ischemic cardiomyopathy, dilated cardiomyopathy (DCM), atrial fibrillation, or coronary heart disease. In total, 33 plasma proteins were prioritized, including repurposing candidates for DCM and/or HF: IL18R (providing indirect evidence for IL18), I17RA, GPC5, LAMC2, PA2GA, CD33, and SLAF7. In addition, 13 of the 25 druggable proteins (52%; 95% confidence interval, 0.31 to 0.72) could be mapped to compounds with known oncological indications or side effects. These findings provide leads to facilitate drug development for cardiac disease and suggest that cardiotoxicities of several cancer treatments might represent mechanism-based adverse effects.